Indications for Use

• Treatment of HIV-1 infection in adults and adolescents aged 12 years and older as part of combination antiretroviral therapy.
• Pre-Exposure Prophylaxis (PrEP): Reducing the risk of HIV infection in individuals at high risk of exposure.

Contraindications

• Hypersensitivity to tenofovir, emtricitabine, or any excipients of the product.
• Severe renal impairment (creatinine clearance <30 mL/min).
• Concurrent use with other antiretroviral drugs containing tenofovir or emtricitabine.

Adverse Effects

Common:

• Headache, nausea, vomiting, diarrhea, fatigue, rash.

Rare:

• Lactic acidosis, hepatic steatosis, osteoporosis, renal impairment.

Very rare:

• Rhabdomyolysis, pancreatitis, allergic reactions (facial swelling, rash).

Recommendations for Use

Administration:

• Take the tablet orally with sufficient water, preferably with food.

Precautions:

• Conduct HIV testing before initiating therapy.
• Regularly monitor renal function, viral load, and bone metabolism markers during treatment.
• Avoid concurrent use with nephrotoxic drugs.

Special Instructions:

• This medication does not provide complete protection against HIV infection. Use additional barrier contraception methods.
• If symptoms of lactic acidosis occur (e.g., weakness, abdominal pain, shortness of breath), seek medical attention immediately.
• The medication is not intended for use in children under 12 years of age.

Before starting treatment, consult a healthcare provider and review the full prescribing information.

— Таблетки для перорального применения, покрытые оболочкой
— Одна таблетка в день (для терапии и профилактики)
— Применяется с другими АРВ-препаратами в составе схемы или как монотерапия в PrEP